{"schema_version":"secwatch.filing_event.v1","accession":"0001539497-21-001048","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2021-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.132147+00:00","generated_at":"2026-06-30T04:47:38.415615+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Bioxytran director Henry Esber resigns; Hana Chen-Walden appointed to board","bullets":["Dr. Henry Esber resigned as director effective July 15, 2021, for medical reasons.","Hana Chen-Walden, M.D., a Medical Advisory Board member, elected to fill the vacancy.","Dr. Chen-Walden has 35+ years of regulatory experience; she will receive no cash compensation as director."],"urls":{"canonical":"https://secwatch.observer/filing/0001539497-21-001048","json":"https://secwatch.observer/filing/0001539497-21-001048.json","markdown":"https://secwatch.observer/filing/0001539497-21-001048.md","text":"https://secwatch.observer/filing/0001539497-21-001048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/0001539497-21-001048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/n2583-x7_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:47:38.415615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c6d256e66","claim":"Henry Esber resigned as Director at BIOXYTRAN, INC.","evidence_excerpt":"Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/0001539497-21-001048-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"83f2ad6931","claim":"Hana Chen-Walden was elected as Director at BIOXYTRAN, INC.","evidence_excerpt":"The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445815/000153949721001048/0001539497-21-001048-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}